<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016847</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00018748</org_study_id>
    <nct_id>NCT01016847</nct_id>
  </id_info>
  <brief_title>Moderate to Persistent Asthma in the Obese Subject</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to Evaluate the Effect of the Leukotriene Antagonist (Singulair©) Plus Moderate Dose Beclomethasone Compared to High Dose Beclomethasone in Obese Subjects With Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is associated with increased airway inflammation and asthma severity that results in
      suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS).
      The investigators suggested that the addition of Singular (montelukast)[LTRA] to moderate
      doses of inhaled corticosteroids will improve asthma control. This cross over study will be
      treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will enter the 2-week run-in period after meeting eligibility criteria at the
      screening visit (visit 1). During run-in subjects will have all usual asthma medications
      discontinued and will be placed on inhaled corticosteroids at moderate doses and leukotriene
      receptor antagonists will be withdrawn (LTRA wash-out). Subjects will be monitored to rule
      out any acute infection or symptoms consistent with an exacerbation. The run-in period will
      be used to assess subject compliance and understanding of study related procedures. Following
      the run-in, to be eligible for the randomization subjects must have an ACQ score &gt;1.25 on the
      Juniper Asthma Control Questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll enough study subjects. Study has been terminated
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Adiponectin, Leptin, Tumor Necrosis Alpha (TNF-α) and Interleukin 6 (IL6) Levels</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Exacerbation</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
    <description>Asthma exacerbation is defined as the development of an increase in asthma symptoms which results in an increase in the use of asthma medications (typically inhaled corticosteroids and/or parenteral corticosteroids) or the addition of another new asthma medication or antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Cell Counts and Differentials</measure>
    <time_frame>Baseline/randomization to week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>leukotriene receptor antagonist (LTRA) montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>High dose of inhaled steroid administered with sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg Q day</description>
    <arm_group_label>leukotriene receptor antagonist (LTRA) montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Sugar pill that looks like Montelukast that will be given Q day</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate persistent asthma as defined daily symptoms, nocturnal awakenings &gt;1
             time/week but not daily, daily short-acting beta agonist usage

          -  pre-bronchodilator Force expiratory volume (FEV1)&gt;55% but &lt;90%.

          -  Subjects must be on controller therapy for asthma with ICS for at least one month
             prior to enrollment.

          -  methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml)
             on ICS within 6 months prior to entry

          -  physician diagnosis of asthma for at least one year prior to study enrollment.

          -  Obesity defined as BMI greater than 30.

          -  subjects must have an Asthma Control Questionnaire (ACQ) score &gt;1.25 on the Juniper
             Asthma Control Questionnaire (indicating poor asthma control),

          -  require daily medications for asthma and be compliant with study related medications.

        Exclusion Criteria:

          -  Subjects must not have been intubated in the last 5 years or unstable asthma symptoms
             resulting in significant loss or work or school

          -  upper or lower respiratory tract infection within 1 month of the study

          -  use of antibiotics within 4 weeks of the study

          -  use of oral glucocorticoids within 4 weeks

          -  use of theophylline

          -  smoking history greater than 10 pack years or any cigarette use within the past two
             years

          -  significant non-asthma pulmonary disease or other medical problems

          -  Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment
             date will be excluded since weight loss is a potential confounder of asthma control

          -  Pregnant women will also be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke Asthma Allergy and Airway Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <results_first_submitted>November 7, 2014</results_first_submitted>
  <results_first_submitted_qc>November 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2014</results_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>38 subjects enrolled in study. Of the 38 subjects 10 were screen failures, and 25 were withdrawn during the 2 week run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
          <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
          <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.</title>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Adiponectin, Leptin, Tumor Necrosis Alpha (TNF-α) and Interleukin 6 (IL6) Levels</title>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Adiponectin, Leptin, Tumor Necrosis Alpha (TNF-α) and Interleukin 6 (IL6) Levels</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study</title>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Exacerbation</title>
        <description>Asthma exacerbation is defined as the development of an increase in asthma symptoms which results in an increase in the use of asthma medications (typically inhaled corticosteroids and/or parenteral corticosteroids) or the addition of another new asthma medication or antibiotics.</description>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Exacerbation</title>
          <description>Asthma exacerbation is defined as the development of an increase in asthma symptoms which results in an increase in the use of asthma medications (typically inhaled corticosteroids and/or parenteral corticosteroids) or the addition of another new asthma medication or antibiotics.</description>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Cell Counts and Differentials</title>
        <time_frame>Baseline/randomization to week 16</time_frame>
        <population>Due to insufficient accrual, data analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
            <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Cell Counts and Differentials</title>
          <population>Due to insufficient accrual, data analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to week 16</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leukotriene Receptor Antagonist (LTRA) Montelukast</title>
          <description>Montelukast (LTRA) administered with moderate dose of inhaled steroid
Montelukast: 10 mg Q day</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>High dose of inhaled steroid administered with sugar pill
Sugar pill: Sugar pill that looks like Montelukast that will be given Q day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early terminiation due to poor enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Monica Kraft, M.D.</name_or_title>
      <organization>Duke Asthma Allergy and Airway Center</organization>
      <phone>9194790719</phone>
      <email>denise.beaver@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

